Powered by Ashby at Quantile Health

Job description

The full description lives on the employer’s site. Open the listing.

Mission-driven: Direct impact on getting life-changing gene therapies to patients who need them.
Small, agile team (~7 employees) with high growth trajectory – opportunity to wear multiple hats and shape the company.
Hybrid/remote flexibility: Described as a hybrid workspace (Built In), with some roles (e.g., Prior Authorization Specialist) listed as fully remote.
Hiring for technical roles (Data Scientist, AI Data Scientist) in New York, indicating investment in AI and data infrastructure.
Culture: Emphasis on innovation, healthcare access, and using AI to solve real-world problems.

One-liner: Quantile Health provides an AI-powered reimbursement platform that automates utilization management and enables subscription-based access agreements for gene therapies between drug manufacturers and payers.
Entity Type: Private (Seed stage, raised $6M–$7.7M)
Headquarters: Albany, New York, United States (also listed as New York, NY)
Founded: 2021 (some sources cite 2022)
Founders: Yutong Sun (CEO), Andrew W. Lo (MIT professor), Peter D. Hancock (former AIG CEO); key team also includes Jonathan H. Gruber (Chief Policy Officer, MIT professor)

Primary industry: Healthcare finance / healthtech / pharmaceutical reimbursement
Target customers: B2B – drug manufacturers (especially gene therapy), self-insured employers, health plans, and other payers
Mission: “Get life-changing medicines to patients faster” by removing financial and administrative barriers to gene therapy access

Maxwell – AI Rebate Agent: An AI agent that automates utilization management (UM) validation, giving manufacturers real-time insights into patient access challenges and reducing manual work. Improves gross-to-net outcomes.
Subscription-based Payment Platform: Enables manufacturers to offer gene therapies via a subscription model directly to health plans, targeting the self-insured employer market (over 100 million lives). Provides steady cash flows and expands patient access.

Valuation/Market Cap: Not disclosed
Key Metric: Total funding – $6M (Seed VC, per CB Insights) or $7.7M (Venture Round, per LinkedIn) — conflicting reports; latest round closed in January 2024
Notable Investors/Partners: Correlation Ventures, Munich Re Ventures, First Round Capital
Growth Signals: Headcount grew +175% YoY (now ~7 employees); actively hiring for Data Scientist, Senior Data Scientist, Prior Authorization Specialist, and AI roles; launched Maxwell AI agent; planning to offer a subscription product in 2025

First-mover in AI-driven UM validation for gene therapy reimbursement, reducing manual work for manufacturers.
Subscription model that aligns incentives between manufacturers and payers, solving the “coverage blind spot” for self-insured employers.
Founding team with deep expertise: former Oscar Health data scientist (CEO), MIT finance professor, former AIG CEO, and MIT health economist.
Patents filed around alternative payment systems for pharmaceutical therapies.

Expand adoption of Maxwell across more manufacturers and payers.
Launch and scale the subscription-based payment product to increase patient access.
Continue building data infrastructure to automate gross-to-net reconciliation and reduce rebate slippage.

Sources